ALPMY
MRK
PFE
Europe just gave Merck a very loud “almost there”
Merck’s Keytruda franchise picked up a fresh boost after a European regulatory committee backed its combination with Padcev for adults with resectable muscle-invasive bladder cancer. That’s not the final stamp, but it’s the kind of sign that makes drug investors sit up straighter in their chairs.
The recommendation comes from the European Medicines Agency’s Committee for Medicinal Products for Human Use, which supported using the perioperative combo — including the subcutaneous Keytruda SC version — as both a neoadjuvant and adjuvant treatment around radical cystectomy. Translation: the regimen is moving closer to becoming a standard option for patients in Europe.
The data is doing the heavy lifting
Why the committee said yes? The Phase 3 KEYNOTE-B15 trial did the persuasive work. According to the company, the combo:
- cut the risk of event-free survival events by 47%
- lowered the risk of death by 35%
- delivered a 55.8% pathologic complete response rate versus 32.5% for old-school chemo plus surgery
That’s the kind of clinical package that makes regulators less grumpy and market watchers more optimistic.
Big picture: more runway for Keytruda
This isn’t happening in a vacuum. Merck and its partners have been stacking up bladder-cancer milestones this year, including an earlier European authorization for cisplatin-ineligible patients and a July FDA clearance in the U.S. That means the commercial runway for the Keytruda-Padcev combo keeps getting longer on both sides of the Atlantic.
For investors, the takeaway is simple: Merck keeps turning Keytruda into a wider moat, one approval-ish step at a time. And in pharma, that’s how you keep the cash machine humming.